Shares in Graft Polymer UK PLC nearly doubled on Friday after it said it drug delivery systems would be a focus area after concluding the first phase of its operational review.

Shares in Graft Polymer soared 79% to 0.85 pence each in London on Friday.

The London-based developer and producer of alloyed polymers, biological supplements and drug delivery systems said it intends to seek commercial opportunities for its patented self-nanoemulsifying drug delivery systems platform.

This would enhance the bioavailability, pharmacokinetics, and stability of biopharmaceutical companies’ therapeutics, it said.

Graft Polymer said it is evaluating a shortlist of five entities for potential future commercial collaboration in this space.

The company continues to develop its intellectual property portfolio, supporting its focus on the healthcare industry clients and targeting SNEDDS-related commercial collaboration opportunities.

Copyright 2024 Alliance News Ltd. All Rights Reserved.